NASDAQ$IRMD

IRadimed Corporation · Q1 2026 earnings

Q1 2026 earnings · · Before market open · Investor relations

Briefing

IRMD reported Q1 2026 revenue of $22.0M and net income of $5.8M, with diluted EPS of $0.45.

For Q1 2026, IRMD reported revenue of $22.0M and net income of $5.8M in the quarterly 10-Q. Management discusses segment performance, costs, and liquidity in MD&A.

  • Revenue of $22.0M for Q1 2026.
  • Net income of $5.8M; diluted EPS $0.45.
  • Operating income $7.2M.
  • Operating trends and segment mix are detailed in the quarterly report.
  • Liquidity, capital allocation, and macro exposure are discussed in MD&A.

Headline financials

Total Revenue

$22M

Previous: $19.5M+12.7%
EPS (adj)

$0.45

Previous: $0.37+21.6%
Capital Expenditures

-$403K

Previous: -$3.7M+89.1%
Net Income

$5.82M

Previous: $4.69M+24.1%
Operating Income

$7.24M

Previous: $5.43M+33.2%
Gross Profit

$16.8M

Previous: $14.8M+13.3%

Revenue & EPS history

IRadimed · Revenue · Quarterly

$22M

Q1 2026+12.7%vs Q1 2025
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Forward guidance

The 10-Q does not provide numeric consolidated annual EPS guidance for IRMD. Management commentary in MD&A covers costs, capital, and sector-specific risks.

Tailwinds

  • Management discusses operational priorities and liquidity in the quarterly filing.
  • Segment or product trends are disclosed where applicable to the business model.

Headwinds

  • Macro, input-cost, and interest-rate exposure can affect near-term results.
  • One-time items, impairments, or fair-value marks may distort quarterly comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+2.2%

Avg return

Earnings day

+2.0%

Avg return

5 days after

+2.8%

Avg return

30 days after

59%

30 / 51 earnings

Positive

+32.1%

Q2 2019

Best reaction

-20.0%

Q1 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.5%+3.4%+8.6%
Q4 2025+9.6%+4.0%+3.5%
Q3 2025+9.4%+9.8%+21.3%
Q1 2025-2.3%-3.0%+13.7%
Q4 2024-8.4%-5.8%-13.3%
Q3 2024-8.8%-0.4%+1.9%
Q2 2024-4.9%-6.6%+0.5%
Q1 2024+6.4%+4.0%+1.1%
Q4 2023-6.9%-3.3%-5.2%
Q3 2023+3.5%-1.3%+3.5%
Q2 2023+10.7%+10.4%+9.7%
Q1 2023+8.5%+8.3%+13.0%
Q4 2022+10.1%-0.3%+3.7%
Q3 2022+5.2%+6.0%+9.4%
Q2 2022-1.4%-3.2%-17.8%
Q1 2022-17.2%-21.5%-19.4%
Q4 2021+19.8%+33.5%+24.1%
Q3 2021+6.4%+5.1%+16.8%
Q2 2021+1.0%-1.8%-2.2%
Q1 2021+5.9%+9.2%+3.9%
Q4 2020-7.2%-2.4%-7.8%
Q3 2020+3.1%+2.7%+9.0%
Q2 2020-4.2%-2.7%-7.2%
Q1 2020-7.9%-8.4%+8.1%
Q4 2019+2.4%-0.5%-10.8%
Q3 2019+5.5%+1.9%-8.2%
Q2 2019+32.1%+23.6%+7.1%
Q1 2019-20.0%-15.1%-25.3%
Q4 2018-0.4%-0.9%-12.4%
Q3 2018+1.7%+4.8%+16.1%
Q2 2018+4.6%+9.8%+17.5%
Q1 2018+13.6%+15.1%+17.0%
Q4 2017-6.3%-7.3%-13.6%
Q3 2017+12.2%+7.1%+11.0%
Q2 2017+17.3%+14.9%+18.5%
Q1 2017-3.4%-3.4%-6.2%
Q4 2016-4.0%-2.8%-2.8%
Q3 2016+2.2%+0.5%+22.7%
Q2 2016+2.8%-4.6%-1.2%
Q1 2016-5.6%
Q4 2015-17.1%
Q3 2015+11.6%
Q1 2014+0.2%
Q2 2015+18.6%
Q1 2015+2.2%
Q4 2014+7.2%
Q3 2013+4.9%
Q3 2014+4.9%
Q4 2013-2.3%
Q2 2013-2.3%
Q2 2014-0.4%
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro